U.S. To Assign 15 FDA Inspectors To China In October
This article was originally published in PharmAsia News
The U.S. government plans to assign as many as 15 inspectors to three major cities in China, beginning in October, to conduct U.S. FDA inspections of drug and other regulated products. In an interview, Michael Leavitt, secretary of Health and Human Services, said China still has not solved all the problems it had with safety of items made for export to the United States, but "they moved aggressively to begin making progress." The first inspectors are to be placed in Beijing, Shanghai and Guangzhou, Leavitt said, but added he does not expect many future problems with Chinese-made drugs and other products. (Click here for more
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.